Owkin
Lionel Guillou is an experienced technology and data science leader with a strong background in AI-based diagnostics, particularly in cancer and sepsis detection. Currently serving as VP of Technology Development and Data for Diagnostics at Owkin, Lionel has a proven track record from previous roles at Cytovale, where responsibilities included leading data science teams and managing FDA submissions. Lionel's academic credentials include a Ph.D. in Biomechanical Engineering from École Polytechnique, complemented by advanced degrees from Stanford University and École Polytechnique. Published research in top-tier journals demonstrates expertise in cell mechanics, biophysical properties, and medical interventions. Additional experience includes positions at McKinsey & Company and internships at Ardian, Inc. and Carmat, enhancing a diverse skill set in engineering and business development.
This person is not in any offices
Owkin
6 followers
Owkin believes that medical research should be collaborative, inclusive, and privacy-preserving. Today, Owkin is pioneering AI in healthcare. It leverages its collaborative federated learning software and expert AI capabilities to bring solutions to optimize drug development and improve patient care in oncology. Owkin’s work has been published in Nature Medicine and other top-tier journals. Owkin has raised over $70M from leading VC funds and is now working with the most prominent cancer centers and pharmaceutical companies in Europe and the US. Additionally, Owkin leads several federated learning consortia, including; MELLODDY, to facilitate 'co-opetive' drug discovery between pharma companies, and Healthchain, to allow collaborative research across multiple hospitals. Owkin was co-founded in 2016 by Thomas Clozel, MD, a clinical research doctor and former assistant professor in clinical hematology, and by Gilles Wainrib, Ph.D., an academic pioneer in the field of Artificial Intelligence in biology.